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 Recent systematic reviews assessing the role of rituximab in the 
management of patients with acquired thrombotic thrombocytopenic purpura 
(TTP)1, 2 identified two major observational studies describing relapse following 
rituximab treatment. One report described a significantly decreased frequency 
of relapse in 40 patients who were treated with rituximab within three days of 
diagnosis, in addition to plasma exchange (PEX) and high-dose corticosteroids, 
compared to historical control patients who had not received rituximab.3 The 
other report compared 22 patients who were treated with rituximab for an 
inadequate response following initial treatment with PEX and corticosteroids to 
historical control patients who had not received rituximab; they reported no 
significant difference in relapse frequency related to rituximab treatment.4 Both 
studies had important limitations.1 Control patients were retrospectively 
selected from a time period preceding the patient group receiving rituximab. 
Some patients had a history of previous episodes of TTP. Not all patients had 
ADAMTS13 activity less than 10%. The frequency of corticosteroid use and 
other treatments for TTP was not controlled. A shorter duration of follow-up of 
rituximab-treated patients compared to control patients potentially biased the 
results to observe fewer relapses in the treatment group. We updated our 
previous systematic review1 to February 23, 2016 and identified no additional 
comparable studies of rituximab treatment for TTP.  
 
 We report the experience of the Oklahoma TTP Registry with rituximab 
treatment for initial episodes of acquired TTP. The Registry is an inception 
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cohort of all consecutive patients for whom the Oklahoma Blood Institute (OBI) 
is requested to provide PEX for patients with a clinical diagnosis of TTP.5  Since 
the OBI is the sole provider of PEX for all hospitals in our region, the Registry 
includes all patients without selection or referral bias. All identified patients 
have been enrolled; no patients were excluded.  The Registry is approved by the 
institutional review boards of the University of Oklahoma Health Sciences 
Center and each participating hospital.  
 
 Our report describes all 41 consecutive patients enrolled in the Registry 
with their first episode of acquired TTP, December, 2003 through December, 
2014. The diagnosis of TTP was documented by ADAMTS13 activity less than 
10%. Four (10%) of the 41 patients died with their initial episode: two were not 
treated with rituximab (one died before PEX began, one died during her first 
PEX); two were treated with rituximab (one died of Staphylococcus aureus 
sepsis; one died following failure of multiple agents). Follow-up of 36 of the 37 
surviving patients is complete through 2015. One patient who was not treated 
with rituximab relapsed at six months and then was lost to follow-up. 
 
 Sixteen (43%) of the 37 surviving patients were treated with rituximab for 
their initial episode. Fourteen were treated because they were unresponsive to 
PEX and corticosteroids or they had recurrent thrombocytopenia when PEX 
was stopped. One patient was treated with rituximab because she could not 
return for evaluations. One patient was treated with rituximab (once) and 
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corticosteroids for a diagnosis of primary immune thrombocytopenia five days 
before TTP was diagnosed and PEX was begun; she then had three more weekly 
infusions. Fourteen of the 16 patients received four weekly infusions of 375 
mg/m2. Two patients received only one infusion, one because she developed 
bacteremia and one because of no insurance.  
 
 Comparison of the 16 rituximab-treated patients to the 21 patients not 
treated with rituximab demonstrated no significant differences in demographic 
features, initial clinical data, or the year of their initial episode (Table). The only 
differences were that rituximab-treated patients had more PEX treatments over 
a longer duration and received a greater total dose of corticosteroids, reflecting 
their inadequate response to initial treatment. Two of the 37 patients 
subsequently died, 16 and 30 months following TTP; neither were treated with 
rituximab for their TTP initial episode and neither had relapsed. Both deaths 
were related to systemic lupus erythematosus which preceded TTP.  
  
 The frequency of relapse among the rituximab-treated patients was 
significantly less than among patients not treated with rituximab (P = 0.009, 
Figure).6  Rituximab-treated patients relapsed at 2.5 and 9.9 years after their 
initial episode. Both patients had received four infusions of rituximab for their 
initial episode; they had ADAMTS13 activity less than 10% at the time of their 
relapse and they were re-treated with rituximab. Nine patients not treated with 
rituximab relapsed at 0.4-5.9 years (median, 3.1 years) after their initial 
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episode. Two of six patients who received rituximab for their initial relapses 
relapsed again after 3.0 and 8.6 years; they were again treated with rituximab. 
One of three patients who had not received rituximab for their initial relapses 
relapsed again after 10 months; she was then treated with rituximab. 
ADAMTS13 activity was less than 10% in 11 of 12 relapses; it was not 
measured in one. All 11 relapsing patients have survived.   
 
 Patients treated with rituximab for their initial TTP episode had 
significantly fewer relapses than patients not treated with rituximab, even 
though their initial episodes were complicated by inadequate response to initial 
treatment with PEX and corticosteroids. Compared to the previous reports,3, 4 
our two groups of patients were concurrent. Only patients with their first 
episode of TTP were included. All patients had ADAMTS13 activity less than 
10% at the time of their initial episodes. The patients’ demographics, initial 
clinical data, and the durations of follow-up were not different. The greater 
total dose of corticosteroids given to rituximab-treated patients may have 
confounded our interpretation that rituximab was associated with the 
decreased frequency of relapses.  Other limitations of our data are that there 
was no standard treatment protocol and only selected patients received 
rituximab.  Although these patients were treated in nine different Oklahoma 
City hospitals, one of the authors (JNG) saw each of these 37 patients and 
participated in treatment decisions.  
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 These data do not provide the strength of evidence of a randomized, 
controlled trial. However, since TTP is a rare disorder, it is unlikely that the 
effectiveness of rituximab will be studied in a randomized, controlled trial.  The 
NHLBI Transfusion Medicine/Hemostasis Clinical Trials Network initiated a 
randomized, placebo-controlled trial to evaluate the efficacy of rituximab for 
initial treatment of patients with TTP in 2009;7 the trial was stopped for futility 
after enrollment of only three patients in the first year. The recently reported 
Phase 2 trial of caplacizumab for TTP8 also emphasizes the difficulty of 
conducting a randomized, controlled trial for patients with acquired TTP: 56 
sites in 13 countries required 40 months to enroll 75 patients.      
 
 Although our data documented decreased frequency of relapse when 
rituximab was added to initial treatment with PEX and corticosteroids, we have 
not yet begun to use rituximab as initial treatment for all patients with TTP. 
Excluding the two patients who died with systemic lupus erythematosus, 10 
(53%) of the remaining 19 patients whose initial episode responded promptly 
and completely without rituximab have not relapsed, with a median follow-up 
of 5.7 years (range, 2.5-9.2 years). Because we feel that patients who relapse 
are at greater risk for subsequent relapses, we usually treat patients who have 
relapsed episodes of TTP with rituximab. The values and preferences of both 
patients and physicians are essential for these treatment decisions.   
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Table 1. Comparison of 16 patients who were treated with rituximab for 
their initial episode of TTP to 21 patients who were not treated with 
rituximab, 2003-2014 
Characteristics Rituximab No Rituximab P* 
Patients (No.) 16 21 - 
Age (median, range) 41 (20-79) 38 (18-69) 0.17 
Race (No., % black) 7 (44%) 8 (38%) 0.75 
Gender (No., % female) 12 (75%) 15 (71%) 1.00 
Initial episode, 2009-2014 (No., %) 10 (63%) 11 (52%) 0.74 
Initial clinical data 
Hematocrit (%, median, range) 22 (8-26) 21 (13-33) 0.42 
Platelets (/µL x 103, median, range) 8 (5-29) 13 (4-63) 0.32 
Creatinine (mg/dL, median, range) 1.5 (0.8-6.5) 1.2 (0.8-4.4) 0.12 
LDH (U/L, median, range)  1206 (664-
3319) 
1479 (343-
3519) 
0.73 
Severe neurologic abnormalities 
(No., %) 
8 (50%) 11 (52%) 1.00 
Treatment of initial episode 
   PEX (No.) 16 (5-79) 8 (5-24) <0.01 
   PEX (days from first to last PEX) 21 (5-76) 8 (5-43) <0.01 
   Corticosteroid (No., %) 16 (100%) 21 (100%) - 
   Corticosteroid (high-dose) (No., %) 6 (38%) 3 (14%) 0.14 
   Corticosteroid (total dose, mg) 
   (median, range) 
3975 
(1000-14,070) 
2135 
(300-8870) 
0.03 
   Cyclophosphamide 2 (13%) 0 0.18 
   Vincristine 1 (6%) 0 0.43 
      
Comparison of the patients who did or did not receive rituximab for an initial 
episode of TTP, 2003 – 2014. This patient cohort was selected to begin with the 
first patient who was treated with rituximab for her refractory initial TTP 
episode in December, 2003. LDH (lactate dehydrogenase) values were adjusted 
for an upper limit of normal of 200 U/L. Major neurologic abnormalities were 
primarily transient focal abnormalities; seizures, stroke, and coma also 
occurred. The median time when rituximab was started was day 11 (day 1 is 
the day of the first PEX). One patient was treated with corticosteroids and one 
rituximab infusion for an initial diagnosis of primary immune 
thrombocytopenia (ITP) 5 days before TTP was diagnosed and PEX was started; 
she required only 5 PEX sessions; she completed the course of four weekly 
rituximab infusions. High-dose corticosteroid was methylprednisolone, 1000 
mg/day for 3 days. The total dose of corticosteroid was calculated in 
prednisone equivalents for the duration of the hospital treatment of TTP. Post-
hospital tapering doses of prednisone were not available.  
*Median values were compared by the Wilcoxon Two-Sample Test with t 
approximation. The Fisher Exact Test was used for comparing proportions. 
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FIGURE LEGEND 
Kaplan-Meier analysis of the time to relapse for 16 patients treated with 
rituximab and 21 patients not treated with rituximab for their initial episode of 
TTP.  Two patients have relapsed following rituximab treatment at 2.5 and 9.9 
years. Nine patients who did not receive rituximab have relapsed at 0.4-5.9 
years (median, 3.1 years).  Censored patients who have not relapsed at the time 
of their last follow-up are indicated by hash marks. Two patients not treated 
with rituximab and who had not relapsed died at 16 and 30 months; their 
deaths were related to pre-existing systemic lupus erythematosus. Hash marks 
do not discriminate between two patients treated with rituximab who had the 
same duration of follow-up (1.5 years) and two patients not treated with 
rituximab who had the same duration of follow-up (3.8 years). The difference 
was significantly different (P = 0.009, calculated to account for the two 
competing events of death).6    
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